
RestructuringJul 27, 2026, 04:12 PM
Boston Scientific Approves $700M-$800M Restructuring Plan
AI Summary
Boston Scientific Corporation's Board of Directors approved a new global restructuring program, the 2026 Restructuring Plan, on July 21, 2026. This plan aims to achieve sustained cost efficiencies and support continued growth through supply chain optimization, functional transformation, and organizational structure evolution. The company expects total pre-tax charges of $700 million to $800 million, with $600 million to $700 million in future cash outlays, while anticipating a reduction in gross annual pre-tax expenses by approximately $500 million. The plan, which includes expected headcount reductions, is projected to be substantially completed by the end of 2029.
Key Highlights
- Board approved a new global restructuring program (2026 Restructuring Plan).
- Plan aims to drive sustained cost efficiencies and enable continued growth.
- Estimated total pre-tax charges of approximately $700 million to $800 million.
- Approximately $600 million to $700 million of charges expected to result in future cash outlays.
- Anticipated reduction in gross annual pre-tax expenses by approximately $500 million.
- Transfer costs are estimated at $300 million to $350 million.
- Termination benefits are estimated at $275 million to $300 million.
- Plan activities are expected to be substantially completed by the end of 2029.
Price Impact
More from BSX